Glucose-6-phosphate dehydrogenase deficiency medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glucose-6-phosphate dehydrogenase deficiency}} | {{Glucose-6-phosphate dehydrogenase deficiency}} | ||
{{CMG}}; {{AE}}{{MA}} | {{CMG}}; {{AE}}{{MA}} [mailto:malihash@bidmc.harvard.edu] | ||
==Overview== | ==Overview== | ||
| Line 65: | Line 65: | ||
* '''Pediatric''' | * '''Pediatric''' | ||
==References== | ==References== | ||
| Line 76: | Line 72: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 13:35, 5 September 2018
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency medical therapy On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency medical therapy |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency medical therapy |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency medical therapy |
|
Glucose-6-phosphate dehydrogenase deficiency medical therapy in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency medical therapy |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
|
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2] [3]
Overview
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Medical Therapy
- The mainstay of treatment for is avoidance of the foods such as fava beans and drugs that cause hemolysis.[1]
- Neonatal jundice:
- Mild: no treatment
- Intermediate: phototherapy
- Sever: Exchange
- Blood transfusion in acute phase of hemolysis
- Dialysis in acute kidney failure
- Folic acid for patients with chronic hemolysis
Disease Name
- Adult
- Folic acid: 1 mg daily.
- Pediatric